Howlader N, et al. - Authors evaluated the impacts of molecular subtypes on breast cancer-specific survival using the largest population coverage in the U.S. population. Results suggested that among women with HR⁺/HER2^- subtype, the best survival pattern was seen, followed by HR⁺/HER2+, HR^-HER2⁺, and finally worst survival for the triple-negative subtype. Experts noted a likeliness of divergence of survival curves in stage IV HR⁺/HER2⁺ vs HR⁺/HER2^- subtype to be attributable to major advances in HER2^-targeted treatment. Contrary to conventional thought, better survival was experienced by HR⁺/HER2⁺ subtype vs HR⁺/HER2^- in advanced-stage disease.